Shanghai Junshi Biosciences Aktie [WKN DE: A2N9PC / ISIN: CNE100003FF7]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Shanghai Junshi Biosciences Co., Ltd Registered Shs -H- Unitary Reg S-144A

09.04.22		Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting (GlobeNewswire)
03.04.22		Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for Anti-CD112R Monoclonal Antibody for Treatment of Advanced Solid Tumors (GlobeNewswire)
31.03.22		Junshi Biosciences Announces Full Year 2021 Financial Results and Provides Corporate Updates (GlobeNewswire)
16.03.22		Junshi Biosciences Announces First Patient Dosed in China in Phase III Clinical Trial of VV116 in Treatment of Moderate to Severe COVID-19 (GlobeNewswire)
15.03.22		Junshi Biosciences and Coherus Announce Presentation of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for No (GlobeNewswire)
04.03.22		Junshi Biosciences and Coherus Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell (GlobeNewswire)
10.01.22		Junshi Biosciences and Coherus Expand Immuno-Oncology Collaboration to Include TIGIT-Targeted Antibody (GlobeNewswire)
05.01.22		Junshi Biosciences and DotBio Announce Collaboration to Develop Next-Generation Antibody Therapy with DotBody Module (GlobeNewswire)
13.12.21		Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment (GlobeNewswire)
10.12.21		Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC (GlobeNewswire)
06.12.21		Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12 (GlobeNewswire)
03.12.21		Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List (GlobeNewswire)
30.11.21		Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recur (GlobeNewswire)
15.11.21		Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer (GlobeNewswire)
01.11.21		TopAlliance Appoints Virginia Ellen Maher, MD, as Vice President of Medical Sciences (GlobeNewswire)
01.11.21		Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
19.09.21		Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19 (GlobeNewswire)
17.09.21		Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemother (GlobeNewswire)
15.09.21		Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine (GlobeNewswire)
14.09.21		Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer (GlobeNewswire)
01.09.21		Junshi Biosciences and Coherus Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
31.08.21		Junshi Biosciences Announces 2021 Interim Financial Results and Provides Corporate Updates (GlobeNewswire)
29.08.21		Distribution of Etesevimab/JS016 in the US Reopened (GlobeNewswire)
27.08.21		Junshi Biosciences Announces Acceptance by NMPA of Investigational New Drug Application for the Subcutaneous Injection of Anti-BLyS Monoclonal Antibody (GlobeNewswire)
19.08.21		Junshi and Coherus Biosciences Announce Positive Interim Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Ce (GlobeNewswire)
12.08.21		Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
30.07.21		Junshi Biosciences Announces Acceptance by NMPA of Supplemental New Drug Application for Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carci (GlobeNewswire)
20.07.21		Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines (GlobeNewswire)
20.07.21		Junshi Biosciences and Immorna Announce Joint Venture to Develop Innovative Self-Replicating and Conventional mRNA Therapeutics and Vaccines (GlobeNewswire)
02.07.21		Junshi Biosciences Appoints Wei Qian as Chief Commerical Officer (GlobeNewswire)
28.06.21		Junshi Biosciences Announces NMPA Acceptance of Investigational New Drug Application for JS014 (GlobeNewswire)
04.06.21		Coherus and Junshi Biosciences Announce Toripalimab in Combination with Chemotherapy Met Primary Progression Free Survival (PFS) Endpoint as First Line Treatment for Recurrent or Metastatic Nasopharyn (GlobeNewswire)
29.04.21		Junshi Biosciences and Coherus Announce Toripalimab First-Line Nasopharyngeal Carcinoma Clinical Data to be Showcased in Plenary Session at 2021 ASCO Annual Meeting (GlobeNewswire)
22.04.21		Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study (GlobeNewswire)
12.04.21		NMPA Approves Toripalimab in Patients with Locally Advanced or Metastatic Urothelial Carcinoma who Failed Platinum-Containing Chemotherapy or Progressed within 12 Months of Neoadjuvant or Adjuvant Pla (GlobeNewswire)
30.03.21		Junshi Biosciences Announces Full Year 2020 Financial Results And Provides Corporate Updates (GlobeNewswire)
03.03.21		Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
01.03.21		Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China (GlobeNewswire)
26.02.21		U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy (GlobeNewswire)
22.02.21		NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy (GlobeNewswire)
19.02.21		Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma (GlobeNewswire)
10.02.21		Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19 (GlobeNewswire)
01.02.21		Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada (GlobeNewswire)
26.01.21		New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent (GlobeNewswire)
25.01.21		FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma (GlobeNewswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

voestalpine-Aktie mit Verlusten: Stabile Erdgasversorgung trotz möglicher Unterbrechungen aus Russland

NVIDIA-Aktie profitiert von starkem Plus bei Umsatz und Gewinn

SBO-Aktie rutscht deutlich ab: Schoeller-Bleckmann verzeichnet deutlichen Gewinneinbruch nach drei Quartalen

UNIQA steigert Ergebnis trotz Unwetterschäden - Trennung von Beteiligungen in Albanien, Kosovo und Nordmazedonien - Aktie profitiert

Neuer Rekord: Bitcoin klettert über 99.000 Dollar

Kryptorally setzt sich fort: Bitcoin, Dogecoin, Ethereum & Co. am Donnerstagmittag

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	23.11.2024 18:51
Kaufwert:	EUR
	Hinzufügen Speichern